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INTRODUCTION
Aging is recognized as a complex process, induced 
by intricate interactions between genetic, epigenetic, 
stochastic, and environmental factors. These factors con-
tribute to a loss of molecular fidelity that results from 
the random accumulation of damage (particularly to 
nuclear and mitochondrial DNA) at the cellular, tissue, 
and organ levels and/or to the whole body, compatible 
with the “disposable soma” theory of aging [1]. This 
theory states that both the architecture and functioning 
of physiological processes and regulatory (immune and 
endocrine) systems are modified during aging, which 
leads to a deterioration of homeostatic capacity. In elderly 
people, induced homeostatic processes show increased 
amplitudes and take longer to return to baseline. Accord-
ingly, elderly people are more vulnerable to internal 
and external stressors, frailty, disability, and disease. In 
addition, the decline in DNA integrity, one of the main 
types of random damage that reduces cellular fidelity 
and induces cellular senescence, is caused by altered or 
lack of expression of stress resistance and survival genes 
that are involved in the cellular and organismal defense 
to environmental stresses, and which maintain homeo-
stasis [2]. However, wide variations have been observed 
in the occurrence, complications, speed, and age- and 
gender-specific manifestation of the aging process 
occurring at the cellular, tissue, and organ levels, and/or 
in the whole body both within and between individuals 
of the same species or of different species. In humans, 
there are individuals aged ≥ 90 years who are still in 
good mental and physical condition, and others who 
show cognitive difficulties and/or the onset of chronic 
inflammatory diseases, such as Alzheimer disease (AD), 
cardiovascular disease (CVD), type 2 diabetes mellitus 
(T2DM), and cancer at age ≥ 60 years [3].
The large heterogeneity in the aging rate in humans 
has been ascribed to genetic and different environ-
mental factors. However, the overall impression is that 
environmental factors are the major determinants of 
both aging and age-related diseases [3,4]. No genetic 
program has emerged to explain the aging process [4]. 
This  conclusion is based on studies on the heritability of 
age-related diseases and aging. In particular, they sug-
gest that the heritability of age-related disease is similar 
to current estimates of the heritability of life expectancy 
[5,6]. Population-based and twin studies on late-onset 
disorders such as AD, cancer, CVD, and T2DM indicate 
that heritability is less than 40% [6]. Lifespan studies in 
worms and mice suggest heritability to be 10–35% [5]. 
Most literature reviews on human life expectancy are 
based on Scandinavian twin studies that estimate heri-
tability at about 25–33% [7,8]. However, this relatively 
small genetic contribution does not imply that genes are 
irrelevant. On the contrary, modern genetic techniques 
identified mutations in familial forms of AD that have 
helped to unravel the molecular mechanisms of disease, 
such as the toxicity of amyloid beta peptide and poten-
tial therapeutic targets in more common sporadic late-
onset AD [9]. Thus, genetic contributions to aging and 
diseases of later life are probably complex and the effects 
of individual genes are probably weak [4]. Furthermore, 
there is a distinction between the genetics of aging and 
exceptional longevity. Human genome-wide genetic 
analyses have revealed only a few age-related loci and 
polymorphic longevity genes [10–12]. Among these, 
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current promising candidates are sirtuins and forkhead 
box O proteins (FOXOs), and the field of epigenetics. 
Functional genomics has revealed a group of genes that 
are differentially expressed in aging, such as immune/
inflammatory genes [13].
Another critical point emerging from the above obser-
vations is that in humans biological age rather than 
chronological age is a better determinant of both the 
aging rate and onset of the common diseases of later life 
[14]. This concept opened an important area of research 
focused on addressing the complex question of whether 
aging should be considered the “cause or effect of dis-
ease,” and, consequently, eliminating the confusing influ-
ence of disease from research into aging. With the aim 
of resolving this dilemma, over the last few decades ger-
ontologists have focused their efforts on measuring bio-
logical aging by identifying potential molecular targets 
as biomarkers of human aging [15]. On the one hand, this 
might finally cast light on the paradigm “aging: a cause 
or effect of disease” and, on the other hand, it could 
identify potential treatment strategies. The hypothetical 
treatment of aging could retard or prevent age-associated 
diseases, resulting in widespread health and social and 
economic benefits. Such treatments could include genetic 
engineering, such as gene therapy or endogenous gene 
repair, pharmacological therapies, or changes in lifestyle.
Many of these aspects are summarized in this chapter. 
Particular emphasis is given to describing the cellular 
and serum biomarkers of inflammation. In particular, 
the data discussed in this chapter are based on expert 
opinion derived from the author’s findings derived from 
studies on age-related diseases and inflammation.
AGING BIOMARKERS: DEFINITION  
AND SELECTION CRITERIA
To date, when one talks about a biomarker, one refers, 
as established officially by the National Institutes of 
Health, to a “feature objectively measured and evaluated 
as an indicator of normal biologic processes, pathogenic 
processes, or pharmacologic responses to a therapeutic 
intervention” [16].
In the case of the aging process, this definition might 
concern measures related to physical changes, such as 
gray hair, reduced skin elasticity, wrinkles, reduced 
muscle strength, or changes affecting near vision, which 
are thought to result from molecular mechanisms occur-
ring in old age [17]. However, these changes reflect 
chronological age rather than biological age. Biological 
age represents the most important indicator of health 
and potential lifespan [14]. Consequently, in consider-
ing these changes as aging biomarkers, the problem of 
measuring the real age of an individual remains. A bio-
marker of real aging should preferably reflect a process 
associated with aging, be easily reproducible in cross-spe-
cies comparisons, and be easily obtainable. In addition, 
more than one biomarker of aging should be considered, 
since aging is assumed to be the consequence of deterio-
ration of more than one system or process. This assump-
tion leads to the decision to preferentially use “panels” 
of biomarkers associated with conditions, alterations, or 
changes to a set of critical systems to assess the biological 
age of any organism [15,17].
Gerontologists began to face this problem in the 
early 1980s, with the development of a large number of 
aging biomarkers [15,17]. Despite numerous efforts and 
the support of this research by the National Institute of 
Aging, to date most biomarkers, including inflammatory 
markers, hormones, markers of oxidative stress, and 
telomere shortening are still under discussion [15,17]. 
In addition, most (perhaps all) markers have not been 
supported by longitudinal studies in humans. Moreover, 
they have been developed for a variety of purposes, 
which are not sufficiently defined. Most investigators 
have used biomarkers as tools for comparing rates of 
aging between different populations or between sub-
groups of a single population. In contrast, others have 
sought biomarkers for identifying individual predisposi-
tion to aging. The latter is much more challenging, prin-
cipally because aging, as a biological process, is not well 
defined at the individual level. Furthermore, searching 
for comparative or predictive biomarkers has resulted 
in the attempted use of panels of measures associated 
with survival, healthy old age, frailty, and age-related 
(multi)morbidity and mortality [15,17]. Classic examples 
of these panels are indicators of physical function, body 
mass and composition, inflammation, endocrine func-
tion, and micronutrient status.
Besides, none of the identified biomarkers is a “true” 
biomarker of aging: most biomarkers are related not 
only to aging but also to diseases. Several biomarkers 
have indeed been developed and tested for conditions 
for which biological age is the single biggest risk fac-
tor, such as peripheral blood cellular telomere length, 
which is an indicator of immunosenescence and does 
not correlate with disease-specific diagnoses. In addi-
tion, biomarkers of age-related diseases and aging have 
been documented only in young-old populations (typi-
cally aged 60–85), and not in the oldest old (aged 85 and 
above) [15,17]. For example, it has been demonstrated 
that blood pressure, indicators of metabolic syndrome, 
and telomere length do not associate significantly with 
age-related morbidity or mortality in population-based 
studies of the oldest old [18–20]. Thus, in general, the 
utility of biomarkers of aging and age-related diseases 
for understanding the health trajectories of the oldest old 
is unexplored territory. It is important that this gap is 
filled, given the rapid growth in the number of very old 
people in many contemporary populations.
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In order to clarify, it is important to know not only 
how such a biomarker is defined, but also the criteria 
for its selection. Accordingly, the American Federation 
for Aging Research has proposed detailed criteria, which 
have been recently reviewed by Johnson [17] and Sprott 
[15] (see Table 1.1). Based on these criteria, a true bio-
marker of aging, in order to be both accurate and use-
ful, should predict a person’s physiological, cognitive, 
and physical function in an age-related way. At the same 
time, it should be easily testable and not harmful to test 
individuals. For example, it could be a blood test or an 
imaging technique that can be performed accurately and 
reproducibly without the need for specialized equip-
ment or techniques. Preliminary testing should be done 
in laboratory animals, such as mice, and then in humans. 
Thus, a biomarker needs to be simple and inexpensive 
to use. It should cause little or no pain or stress [15,17].
Furthermore, current clinical and basic research into 
aging biomarkers is designed to exchange knowledge 
and resolve differences between these fields by making 
comparisons between clinical and basic research data. 
On the other hand, biomarkers represent a hot topic and 
have the ability to change our lives, if real predictions 
about individuals are made possible in the future.
INFLAMMATORY NETWORK: A 
DESCRIPTION AND ITS BIOLOGICAL 
EFFECTS ON AGING
The immune system has evolved to defend the host 
against microbial invasion, and to counteract  tissue 
damage elicited by chemical or physical agents or 
trauma, thus maintaining tissue homeostasis and repair 
[21]. In both conditions, it is able to respond appro-
priately by inducing appropriate reactions, the inflam-
matory responses [21,22]. These can be induced under 
different stimuli and can be initially evoked as localized 
tissue reactions and subsequently as systemic cytokine-
induced reactions [i.e. leukocytosis, fever, somnolence, 
anorexia, activation of hypothalamic-pituitary-adrenal 
axis, increased level of glucocorticoids, and acute-phase 
synthesis, e.g. of C-reactive protein (CRP) in the liver]. 
These characterize the so-called “acute-phase reaction.” 
Inflammatory responses are orchestrated by a complex 
network of molecules (the mediators) and cells, which 
work together to mediate the activation of different sig-
naling pathways and the expression and transcriptional 
regulation of hub genes. Such hub genes receive and 
direct the activity of many other genes [21,22].
Recent studies on the topology of the inflammatory 
network suggest a key role for some mediators in driv-
ing the different cellular interactions and regulating the 
type of inflammatory reaction. Several pro- and anti-
inflammatory mediator molecules are involved [23]. 
Their release is modulated by different factors, such 
as the type and load of the inflammatory agent, and 
the activation of different receptor sensors and signal-
ing pathways, such as the well-known nuclear factor 
(NF)-κB pathway [24,25]. In addition, the magnitude of 
their production has been demonstrated to exhibit inter-
individual variation resulting from genetic heterogene-
ity. Single nucleotide polymorphisms (SNPs) in several 
genes and epigenetic factors are involved in regulating 
the pattern of inflammatory mediator activation [26]. 
Among the inflammatory mediators, tumor necrosis fac-
tor (TNF-α), interleukin-1 (IL-1), and IL-6 have impor-
tant roles. These are classic proinflammatory cytokines 
involved in inducing both local and systemic effects. 
Locally, they contribute to both activation and local 
recruitment of inflammatory cells by working together 
with chemokines, which induce expression of adhesion 
molecules [27]. When inflammatory reactions are caused 
by high-intensity stimuli, the production of cytokines is 
increased and they are released into the circulation, thus 
provoking the acute-phase response. In contrast, anti-
inflammatory cytokines, such as IL-10, damp down the 
activity of inflammatory cells by inhibiting the release 
of proinflammatory cytokines and therefore turning off 
inflammatory processes [28].
If tissue health is not restored in response to stable 
low-grade irritation, inflammation can become a chronic 
condition that causes continuous damage to the sur-
rounding tissues. In fact, during chronic inflammatory 
immune responses, tissue injury and healing proceed 
simultaneously. The collateral damage caused by this 
type of inflammation usually accumulates slowly, some-
times asymptomatically for years, but can eventually 
lead to severe tissue deterioration [29].
The inflammatory response is not a negative phenom-
enon per se. It has evolved to neutralize infectious agents 
by playing a beneficial role until the time of reproduc-
tion and parental care. In contrast, in old age, a period 
largely unforeseen by evolution, it can lead to a detri-
mental effect through chronic inflammatory responses 
(“antagonistic pleiotropy”) in several/all tissues and 
organs; these are the cause of both the aging pheno-
type and chronic diseases [23,29]. Low-level, chronic 
TABLE 1.1 selection Criteria for an Aging Biomarker
1 It must predict the rate of aging. Operationally, it must be a 
better predictor of lifespan than chronological age alone.
2 It must monitor a basic process that underlies the aging 
process, not the effects of diseases.
3 It must be able to be tested repeatedly without harming the 
person; for example, a blood test or an imaging technique.
4 It must be something that works in both humans and laboratory 
animals. So, it must be tested in laboratory animals before being 
validated in humans.
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inflammation, or “inflammaging,” is characterized by a 
two- to fourfold increase in serum levels of inflamma-
tory mediators and accompanies the aging process [30]. 
It can be used as a predictor of mortality and, as men-
tioned above, it is recognized as a critical risk factor in 
the pathogenesis of several age-related chronic diseases 
such as AD, CVD, frailty, functional disability, T2DM, 
and sarcopenia [31–33].
Several contributory factors have been associated 
with low-grade inflammatory activity in elderly popu-
lations, including augmentation of age-related body 
fat and a consequent increase in visceral adiposity, age-
related decline of sex hormones, oxidative and genotoxic 
stress, cellular and tissue damage, changes in nutrition, 
alterations in the physical condition of gut microbiota, 
and changes to other organs (brain and liver) and sys-
tems (immune and endocrine) [31–33]. In addition, 
factors that promote physiological stress, such as long-
term smoking and depression, also seem to contribute 
to elevated inflammation [31–33]. However, the most 
important factor affecting age-related inflammation is 
the life-long pathogen burden [29]. Accordingly, some 
recent studies have linked an individual’s exposure 
to past infection to levels of chronic inflammation and 
increased risk of heart attack, cancer, and stroke [31,33]. 
In contrast, some evidence suggests persistent periph-
eral multibacterial infection, such as periodontitis, asso-
ciated with gram-negative anaerobic bacteria capable of 
exhibiting localized and systemic infections in the host, 
as a possible aggravating cofactor in subjects with vas-
cular diseases and as a risk factor for the onset of other 
age-related diseases, such as AD [29].
Of special note is inflammaging in centenarians, whose 
data seem paradoxical. Centenarians have increased 
 levels of both inflammatory and anti-inflammatory 
mediators and significantly different frequencies of pro-
tective genotypes from old subjects [29,34]. Therefore, 
it is necessary to identify appropriate molecular targets 
as biomarkers likely to be present in long-lived subjects 
and capable of simultaneously influencing different 
organs of the body with pleiotropic characteristics. This 
might permit a preferential and selected development of 
pleiotropic therapeutic interventions capable of acting 
concomitantly on different targets and at different levels.
CELLULAR INFLAMMATORY 
BIOMARKERS
As above mentioned, aging is not a genetically pro-
grammed process [4]. On the contrary, it is considered 
to be an entropic process, involving the loss of molec-
ular fidelity and subsequent accumulation of waste 
products [2,35]. In addition, it is now thought that dur-
ing evolution the host defense and the aging processes 
have become linked [2]. As a consequence, host defense 
mechanisms seem to be involved in the aging process 
and activate the inflammatory network to induce the 
so-called senescence-associated secretory phenotype (SASP), 
which is represented by a myriad of factors, including 
proinflammatory mediators [36]. A large array of defense 
factors and mechanisms characterize the inflammatory 
network and all (or most) are linked to the NF-κB sys-
tem, an ancient specialized signaling pathway involved 
in host defense [24,25]. In particular, the NF-κB system 
is a cytoplasmic sensor that can be activated by both 
immune attack and a plethora of external and internal 
danger signals, such as a oxidative and genotoxic stress 
and tissue injuries [24]. Thus, the NF-κB system is at the 
hub of the aging inflammatory network; NF-κB activa-
tors are pro-aging factors. Sustained NF-κB activation 
seems to be associated with advancing age. As a result of 
harmful responses (e.g. chronic inflammatory responses, 
increased apoptotic resistance, decline in autophagic 
cleansing and tissue atrophy), sustained NF-κB activa-
tion can elicit a host defense “catastrophe” (by activat-
ing several inflammatory and entropy pathways) that 
improves both the aging process and the risk of develop-
ing age-related degenerative diseases (Fig. 1.1) [2,36,37]. 
In light of this evidence, research into aging has focused 
on identifying pro-aging factors, the “NF-κB activators,” 
as hypothetical cellular inflammatory biomarkers. Some 
of these will be described next.
Mitochondrial Dysfunction, Oxidative Stress, 
Activation of Inflammasomes, and Decline of 
Autophagic Cleansing
Upon aging, mitochondrial alterations are observed, 
including increased production of oxidation molecules 
and diminished functional activity; this condition is 
termed dysfunctional mitochondria [38,39]. An increase 
in mitochondrial oxidation seems, indeed, to accom-
pany aging, with protein carbonyls, thiobarbituric 
acid reactive substances, ROOH, and 8-hydroxy-2′-
deoxyguanosine being the major markers. Mitochondrial 
dysfunction and oxidative stress are, hence, associated 
with the aging process, but also with the pathogenesis 
of several diseases, i.e. metabolic and neurodegenera-
tive diseases. These effects are commonly attributed to 
disturbances in energy metabolism, increased reactive 
oxygen species (ROS) production, and the crucial role 
of mitochondria in apoptotic cell death. In addition, 
mitochondria dysfunction and oxidative stress seem to 
provoke and potentiate inflammatory responses, even 
if the mechanisms remain elusive [38,39]. However, 
recent findings provide evidence for a crucial role for 
mitochondria in the regulation of innate immunity/
inflammatory responses through different mechanisms 
[40,41]. The first is mediated by ROS, which can induce 
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the assembly of multiprotein inflammatory complexes 
called “inflammasomes” [38,39,42]. Nod-like receptor pro-
tein 3 (NLRP3) is a component of these complexes and 
is a major sensor of cellular stress signals, e.g. ROS. Its 
activation triggers the caspase-1-mediated maturation of 
precursors of the IL-1β and IL-18 cytokines [42]. Thus, 
an endogenous stress-related inflammatory response 
is induced, termed “para-inflammation” by Medzhitov 
[43]. However, the exact mechanism involved in ROS-
induced NLRP3 activation is still unclear. Zhou and col-
leagues demonstrated that oxidative stress can activate 
NLRP3 inflammasomes via redox regulation of the thio-
redoxin/thioredoxin-interacting protein balance [44]. It 
is also possible that ROS directly oxidizes thiol groups in 
the leucine-rich repeat domain of NLRP3 to activate the 
inflammasomal pathways. In addition, mitochondria (1) 
are involved in the control of antiviral RIG-like receptor 
signaling pathways; (2) contain NLRX1 receptors, which 
monitor ROS production; and (3) secrete several damage-
associated molecular patterns (DAMPs) following loss 
of their integrity, such as ROS, ceramide,  mitochondrial 
DNA, and formyl peptides, which can provoke local and 
systemic para-inflammatory responses by inflamma-
somes via NLRP3 [40,41].
All of these observations emphasize that disruption 
of mitochondrial integrity and a deficiency in cellular 
housekeeping can trigger NLRP3 and NLRP1 (another 
member of inflammasomes) activity in some tissues, 
such as brain, and by this means stimulate inflamma-
tion [38,39]. In this respect, the effective autophagic 
uptake and lysosomal degradation of dysfunctional 
mitochondria form a crucial element in maintaining tis-
sue homeostasis [37]. Autophagy is, indeed, an ancient 
housekeeping mechanism that controls cellular homeo-
stasis by facilitating the removal of misfolded proteins 
and dysfunctional organelles, such as mitochondria [37]. 
There are indications that autophagic capacity is com-
promised in aging and age-related diseases, e.g. AD, as 
proposed in the “garbage can” hypothesis of Brunk and 
Terman [45]. On the other hand, there is growing evi-
dence that inflammasomes are activated under many 
pathological conditions; thus, a deficiency in autopha-
gic housekeeping could trigger activation of an inflam-
matory component and promote pathogenesis [37–41]. 
Decline of
autophagic
cleansing: induction
        of mTOR
Activation of
innate/inflammatory immunity
 by PAMPs and DAMPs and
 release of IL-6 and TNF-α
Elevated activation of
insulin/IGF signaling
Dysfunctional
mitochondria
Oxidative stress
        (ROS)
ROS
Activation of NLRP3
     inflammasome
Genotoxic stress
(NEMO shuttle, PARP-1)
Acetylation,
O-glycosylation
  Mitochondrial DAMPs:
mtDNA, ceramide, formyl
              peptides
NF-κB
Entropic ageing process and release of
                        SASP
FIGURE 1.1 NF-κB system activation is at the hub of the aging inflammatory network. NF-κB system activation is induced by different 
factors, such as mitochondria dysfunction, oxidative stress, activation of inflammasomes, decline of autophagic cleansing, activation of innate/
inflammatory responses by pathogen-associated molecular patterns (PAMPs) and damage-associated molecular patterns (DAMPs), elevated in-
duction of insulin/insulin-like growth factor I (IGF-I) pathway, acetylation, O-glycosylation of components of the NF-κB pathway, and genotoxic 
stress. The NF-κB system induces the aging process and release of the senescence-associated secretory phenotype (SASP). IL-6, interleukin-6; 
NEMO, NF-κB essential modulator; NLRP3, Nod-like receptor protein 3; PARP-1, poly (ADP-ribose)-polymerase 1; ROS, reactive oxygen species; 
TNF-α, tumor necrosis factor.
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After 10 years of experimental work, the garbage can 
hypothesis still seems to be valid, since different research 
approaches have clearly demonstrated both the decline 
of autophagy and increased mitochondrial dysfunction 
with aging [37,46,47]. Thus, the decline in autophagy 
during aging creates problems in cellular housekeeping 
functions, which stimulate NF-κB signaling and thus, 
directly or via inflammasomes, trigger SASP and the 
inflammatory phenotype [37]. Moreover, there are indi-
cations that inflammatory NF-κB signaling can repress 
autophagy and thus induce the destructive interplay 
between autophagy and inflammasomes [37,38]. For 
instance, TNF-α can induce or repress autophagy in an 
NF-κB-dependent manner. In the presence of NF-κB sig-
naling, TNF-α activates mammalian target of rapamy-
cin (mTOR), a major autophagy inhibitor. In contrast, in 
cells lacking of NF-κB activation, TNF-α stimulates the 
expression of Beclin-1, an enhancer of autophagy [37,38].
Immune Innate Activation by PAMPs and 
DAMPs
During aging, adaptive immunity clearly declines, a 
condition defined as immune senescence [48]. In contrast, 
innate immunity seems to be activated, thus inducing a 
chronic inflammatory phenotype, as mentioned above 
[29]. Innate immunity is activated through the link-
ing of pattern recognition receptors (PRRs), consisting 
of multiligand and evolutionarily conserved recep-
tors [e.g. Toll-like receptors (TLRs), Nod-like recep-
tors (NLRs), and RIG-like receptors (RLRs)], with a 
plethora of both invading pathogen structures, called 
pathogen-associated molecular patterns (PAMPs), 
and endogenous danger molecules, the DAMPs [25]. 
These latter represent the debris from apoptotic cells, 
fragments of extracellular matrix, and abnormal 
 molecular modifications that accumulate during aging 
(26). PRR-dependent innate/inflammatory responses 
induce the release of different inflammatory mediators 
by the NF-κB pathway [24]. Among the PRRs, TLRs 
(mainly TLR2 and TLR4) recognize not only some 
PAMPs but also a large number of different alarmin 
age-type DAMPs, including high mobility group box 
1 (HMGB1), S100, heat shock protein (HSP) 60 and 
HSP70, and defensins [25,33]. In addition, both TLR2 
and TLR4 may play a crucial role in the pathogenesis 
of several age-related diseases [33]. Accordingly, genes 
encoding these molecules seem to modify both the 
susceptibility to age-related diseases and survival to 
extreme age, as recently described in our study [26]. 
Their action seems, at least in part, to be mediated 
by pro/anti-inflammatory genotypes that are able to 
determine the negative or positive control of inflamma-
tion. In contrast, the +896A/G (Asp299Gly; rs4986790) 
and +1196C/T (Thr399Ile; rs4986791) TLR4 SNPs have 
been phenotypically associated with changes in the 
production of pro- and anti-inflammatory cytokines; 
principally, the Asp299Gly SNP seems to have a key 
role in AD, atherosclerosis, prostate cancer, and, recip-
rocally, in longevity [26,33].
In addition, during aging different macromolecules 
(DNA, lipids, and proteins) can be targeted by different 
age modifications; for example, the Maillard reaction, 
a well-known nonenzymatic glycosylation mechanism, 
is induced as a result of the enhancement of oxidative 
stress and hyperglycemia [2]. Interestingly, protein 
glycation products, called AGEs (advanced glycation 
end products), which are considered to be pro-aging 
factors, activate the NF-κB pathway by linking to char-
acteristic PRR receptors, the RAGE receptors (receptor 
for advanced glycation end products). The AGE con-
tent increases in tissues during aging, and the AGE 
process increases in atherosclerosis, diabetes, neu-
rodegeneration, and several inflammatory diseases. 
The major harmful effect of AGE in aging seems to be 
maintenance of the antiapoptotic and proinflammatory 
phenotype. Of special note is the glycation of collagen 
and elastin, which seems to have a key role in vascular 
pathologies [25].
Induction of the NF-κB Signaling Pathway by 
Proinflammatory Cytokines
Activation of innate immunity in the aging process 
(see above) determines the production and release of 
SASP, including different inflammatory molecules. 
Among these, proinflammatory cytokines are mostly 
observed to be elevated in the elderly. These cytokines 
can also activate the NF-κB pathway and in this way can 
propagate and aggravate inflammatory changes. IL-6 
and TNF-α are clearly upregulated with aging, even if 
their exact role in the aging process has been difficult 
to establish because of their complex, cell type-specific 
functions [24].
Insulin / Insulin-Like Growth Factor Signaling
Excessive insulin/insulin-like growth factor (IGF) 
signaling has been demonstrated to enhance and accom-
pany the aging process [2]. On the other hand, suppress-
ing insulin/IGF signaling triggers FOXO signaling, 
thus inducing the long-lived phenotype. Insulin/IGF 
signaling promotes detrimental aging effects via NF-κB 
pathway activation of the IκB kinase α/β complex. As 
a consequence, improved inflammatory responses and 
resistance to apoptosis are induced. Given that inhibi-
tion of the insulin/IGF signaling pathway can activate 
FOXO-dependent lifespan extension, the NF-κB path-
way may have a role in driving the aging process via the 
insulin/IGF axis [49].
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Protein Modification: Acetylation and  
O-Glycosylation
Components of the NF-κB pathway are the targets of 
several post-translation modifications that trigger the 
activation of the pathway, but also regulate the tran-
scriptional efficiency of the NF-κB system [2,24]. Phos-
phorylation and ubiquitylation are the major regulatory 
changes in the activation step. However, acetylation 
and O-glycosylation can control the transcriptional effi-
ciency of the NF-κB system. Interestingly, acetylation 
and O-glycosylation seem to modify the NF-κB path-
way in response to stress. For example, inflammatory 
responses can be potentiated through the acetylation 
of NF-κB components. In addition, increased protein 
acetylation can activate cellular senescence. In contrast, 
sirtuin molecules (see below), such as SIRT1 and SIRT6, 
can deacetylate the p65 component of NF-κB and thus 
repress NF-κB signaling [2,24].
Chronic hyperglycemia seems to induce glucotoxic-
ity through the formation of AGEs or via the production 
O-linked N-acetylglucosamine (O-GlcNac)-modified 
proteins; this suggests glucose as a potential pro-aging 
factor. On the other hand, levels of O-glycosylated pro-
teins increase during aging. In particular, increased 
O-glycosylation of IKKβ protein, which can enhance 
NF-κB activity, has been observed during aging. 
O- glycosylation can also target the p65 NF-κB protein 
and potentiate the transcriptional efficiency of NF-κB com-
ponents. In addition, p53 can inhibit glycolysis and thereby 
suppress the activation of IKKβ/NF-κB signaling [2,24].
Genotoxic Stress
One of the major stochastic aging mechanisms is 
genomic instability [2,50]. DNA lesions appear during 
aging in both nuclear and mitochondrial DNA as a result 
of free radicals and oxidative stress. The major path-
ways activated by genotoxic stress are the p53, NF-κB, 
and PARP-1 [poly (ADP-ribose)-polymerase 1] path-
ways [50]. In particular, activation of NF-κB signaling 
represents one of the principal cellular features induced 
by DNA damage [51]. The DNA damage-dependent 
NF-κB activation cascade is defined as the NEMO 
shuttle, since under genotoxic stress an NF-κB essential 
modulator (NEMO) forms a complex with both PIDD 
(p53-induced protein with a death domain) and RIP-1 
(receptor-interacting serine/threonine-protein) kinase 
[52]. This complex accumulates in the nucleus, and a 
nuclear matrix-associated SUMO E3 ligase (PIASy) then 
sumoylates the NEMO protein. Sumoylation is a prereq-
uisite for ataxia telangiectasia mutated (ATM) kinase-
mediated phosphorylation of NEMO. Subsequently, 
NEMO is desumoylated and the NEMO/ATM complex 
is exported from the nucleus to the cytoplasm, where 
it activates IKK kinases by triggering NF-κB signaling. 
This prevents p53-induced apoptosis, since the IKK 
kinases phosphorylate p53 and induce its degradation 
by proteasomes [52].
Another hallmark of DNA damage is induction of 
PARP-1, a ubiquitously expressed member of the PARP 
family of enzymes that modify proteins by poly(ADP-
ribosyl)lation. PARP-1 is a DNA damage sensor that 
maintains genome integrity by regulating DNA repair 
[53]. In addition, PARP-1 is a novel coactivator of NF-κB 
signaling, which potentiates NF-κB activation by geno-
toxic stress [24,53]. Furthermore, it is one of the proteins 
involved in regulating the length of telomeres, nucleopro-
tein structures located at the ends of chromosomes [53]. 
Telomeres are subject to shortening at each cycle of cell 
division and are highly sensitive to damage induced by 
oxidative stress. During aging, both chronic inflamma-
tion and oxidative stress induce increased base oxidation. 
In contrast to the majority of genomic DNA, there is evi-
dence that telomeric DNA is deficient in the repair of sin-
gle-strand breaks. Thus, oxidative stress causes persistent 
damage to telomeres and a faster rate of telomere short-
ening, which induces cellular senescence and a faster rate 
of biological aging. Since chronic oxidative stress plays 
a major role in the pathophysiology of several chronic 
inflammatory diseases, it has been hypothesized that 
telomere length reduces at a faster rate during oxidative 
stress. On the other hand, telomere shortening is assumed 
to be a biomarker of premature cell senescence in vascu-
lar and metabolic diseases [54,55]. Therefore, telomere 
length as well as the evaluation of PARP-1 function and 
integrity might be useful biomarkers of both biological 
aging and disease onset and progression [53].
SERUM INFLAMMATORY BIOMARKERS
Serum biomarkers (SBs) are commonly defined as 
indicators of physiological or pathological states that 
are detectable in serum. They are generally utilized as 
appropriate and rapid tools for the diagnosis of patholo-
gies and for monitoring therapy or therapeutic efficacy, 
good health status, and systemic status. A wide range of 
SBs related to tissues, organs, and the whole body exists, 
even if none can be considered as sufficiently well-
established and specific to be useful as an ideal aging 
biomarker. Among the SBs, the circulating inflammatory 
components of SASP (i.e. IL-6, TNF-α, proinflammatory 
cytokines, and CRP) are well investigated (see Fig. 1.1). 
These are associated with several chronic aging condi-
tions, such as CVD, T2DM, physical disability, and cog-
nitive decline [29–31].
As mentioned above, IL-6 is a proinflammatory cyto-
kine produced by both lymphoid and nonlymphoid cells, 
such as T and B cells, monocytes, fibroblasts, vascular 
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endothelial cells, adipocytes, skeletal muscle cells, and 
other kinds of cells. Its release and expression are under 
transcriptional regulation mediated by induction of the 
inflammatory response [27].
TNF-α is mainly produced by macrophages, but also 
by other lymphoid and nonlymphoid cells, such as adi-
pocytes, mast cells, fibroblasts, cardiac myocytes, vascu-
lar endothelial cells, and neuronal cells. It induces IL-6 
and IL-8 production and release through the activation 
of different pathways [56,57].
In healthy elderly people, an age-related increase in 
IL-6 and TNF-α levels has been observed. In particular, 
the prospective InCHIANTI study showed a significant 
association between high levels of CRP, IL-1, and IL-6 
and poor physical performance and muscle strength 
[58]. In addition, TNF-α is considered to be an indepen-
dent prognostic marker for mortality in centenarians, 
and in elderly nursing home residents its detection in 
serum may be a predictor of early mortality [59,60].
In centenarians, a linear increase in serum TNF-α lev-
els with CRP and IL-6 has been detected, demonstrating 
inter-related activation of the inflammatory cascade in 
very old people [59]. A specific correlation between the 
above-mentioned cytokines and specific age-related dis-
eases has been demonstrated. In particular, TNF-α seems 
to be associated with AD, insulin resistance, and T2DM 
[60–62]. In addition, high circulating levels of TNF-α and 
IL-6, as well as CRP, have been associated with CVD and 
frailty [63–66].
CRP is a member of the pentraxin superfamily, which 
includes both short and long pentraxins. It is a highly 
conserved plasma protein consisting of five identical 
21,500-Da subunits. It was identified in 1930 as one of 
the first acute-phase proteins. CRP is, indeed, a stable 
plasma marker of systemic inflammation, with a half-life 
of 19 h. During the acute-phase response, its levels may 
rapidly rise up to 1000-fold above reference values. The 
main source of CRP is the liver, even if its production has 
recently been demonstrated in other sites, such as mac-
rophages, kidney, and neuronal and endothelial cells. Its 
production is regulated during acute-phase response by 
the proinflammatory IL-1, IL-6, and TNF-α cytokines. 
Increased CRP levels might be significant predictors of 
T2DM and are related with insulin resistance and meta-
bolic syndrome, as well as with AD [66–69].
MicroRNAs (miRNAs) are small, noncoding regula-
tory RNAs composed of 18–25 nucleotides. They act as 
gene expression regulators, promoting the degradation 
and/or translational inhibition of the mRNA target by 
binding to either the coding region or the 3′ untranslated 
region (UTR). As base pairing is often imperfect, one 
miRNA can regulate many targets, and several miRNAs 
can inhibit a single mRNA. In general, miRNAs regu-
late many physiological processes such as cell prolifera-
tion, development, cell death, cell response, survival, 
and replicative senescence, but they are also involved in 
cancer formation [70,71]. Moreover, some studies have 
demonstrated a role for miRNAs in aging processes, 
and the presence of different miRNA expression pro-
files between young and old people [71]. In addition, 
 miRNAs have been demonstrated to have the capacity 
to modulate age-related inflammation [72]. In particular, 
some miRNAs take part in feedback loops, both regulat-
ing the expression of cytokines and being subjected to 
regulation by NF-κB [73]. One of these is miRNA146a, 
which together with miRNA146b negatively regulates 
the expression of IL-6 and IL-8 in fibroblast and probably 
also acts on IL-1 [74]. Because its expression depends on 
NF-κB, this provides a negative feedback loop. Also, the 
miRNA let-7 inhibits IL-6 expression, but in this case a 
positive feedback loop is established because let-7 is neg-
atively regulated by NF-κB [75]. Moreover, NF-κB may 
be indirectly regulated by miRNAs. Indeed, miRNA21 
negatively regulates the expression of pellino 1, a ubiq-
uitin ligase that acts on IRAK-1 (interleukin-1 receptor-
associated kinase 1), thus activating the downstream 
signaling cascade that leads to the nuclear translocation 
and activation of NF-κB [76]. This means that miRNAs 
could have a role in aging, regulating gene expression, 
and interacting with the NF-κB pathway.
MOLECULES AND MECHANISMS LINKED 
TO THE NF-κB SIGNALING SYSTEM ARE 
POTENTIAL TARGETS FOR ANTI-AGING 
AND ANTI-AGE-RELATED DISEASE 
TREATMENT STRATEGIES
Growing evidence suggests that activation of the 
NF-κB signaling system during aging is responsible for 
inflammaging [30–33,36]. This is plausible since nearly 
all insults that enhance the aging process are well-known 
activators of the NF-κB signaling system, as illustrated 
in Fig. 1.1. The NF-κB signaling system also represents 
the keystone of host defense, receiving input signaling 
from the PRR receptors and subsequently organizing the 
transcriptional output response against the acute danger 
[24,25]. In both cases, sustained activation of the NF-κB 
signaling system can trigger and enhance the aging pro-
cess in many different ways, as described above [2,36]. 
Thus, the NF-κB system is at the hub of the aging pro-
cess. This concept leads us to consider molecules and 
mechanisms linked to the NF-κB signaling system as 
potential aging biomarkers and targets for the develop-
ment of new therapeutic strategies against aging and 
age-related diseases.
On the basis of data reported herein, some inferences 
can be proposed (see Table 1.2). The presence of “high-
risk” levels of IL-6 and TNF-α in elderly people sug-
gests the possibility of developing preventive measures 
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using specific inhibitors, such as monoclonal antibodies, 
against these cytokines and their receptors. A reduction 
in inflammatory mediators may be also induced through 
nonsteroidal anti-inflammatory drug (NSAID) therapy. 
For people who do not respond to (or comply with) 
NSAID therapy, other more sophisticated preventive 
approaches may be possible, including the use of ago-
nists of cytokine receptors or PRR receptors, e.g. TLR2 
and TLR4, particularly in carriers of high inflammatory 
response alleles [26,33]. On the other hand, activation 
of PRR receptors, such as TLR2 and TLR4 by PAMPs 
or DAMPs, particularly upon aging, induce the release 
of a large number of SASP components, such as proin-
flammatory IL-6 and TNF-α cytokines, via the NF-κB 
signaling system [25,33]. In addition, the magnitude of 
cytokine production and of all proinflammatory media-
tors, in general, has been shown to vary between indi-
viduals, probably based on genetic heterogeneity. One 
or more functional SNPs in one or more innate immunity 
genes might be responsible. Accordingly, recent studies 
have suggested a role for the + 896A/G TLR4 SNP in 
cytokine production. In particular, high levels of proin-
flammatory cytokines were observed in carriers of the 
+ 896A/G TLR4 SNP [26,33].
Another possible therapeutic intervention in subjects 
with proinflammatory alleles of TLR2 and TLR4 genes is 
antibody-mediated stimulation of the decoy TLR recep-
tors, such as the tyrosine kinase TAM (Tyro3/Axl/Mer) 
receptors, or of the intracellular TLR regulators [i.e. sup-
pressor of cytokine signaling (SOCS) molecules], which 
are involved in inhibition of the inflammatory response 
by mediating TLR degradation, or activation of competi-
tive or dephosphorylating factors [77]. The sequential 
induction of these pathways and their integration with 
upstream TLR and cytokine signaling networks may 
limit the inflammatory response and maintain innate 
immune system homeostasis. A better understanding 
of the regulatory mechanisms of this cascade may have 
important implications for therapeutic intervention in 
human immune disorders and reduce the risk of devel-
opment of several age-related diseases [26,33].
In addition, it has been demonstrated that statin 
therapy has beneficial effects in reducing primary and 
secondary CVD risk through its lipid-lowering and 
anti-aging actions, such as reducing levels of inflamma-
tory molecules, especially CRP and IL-6. On the other 
hand, results from the Justification Trial Evaluating 
Rosuvastatin (JUPITER) demonstrated that statin treat-
ment in apparently healthy subjects with elevated CRP 
and non-elevated cholesterol low-density lipoprotein 
results in a significant reduction of both these markers 
and CVD [78].
Another possible anti-aging strategy, which may 
reduce the biological effects of NF-κB signaling in 
aging, is caloric restriction (CR) [79]. Restricting the 
intake of calories has been practiced as a method for 
increasing both the length and quality of life for over 
500 years. Experimental work confirming the suc-
cess of this approach in animals has accumulated over 
the last 80 years. CR may extend life by up to 50% in 
rodents, with progressively less impact the later in life 
it is started. This effect is matched by profound impacts 
on age-related diseases, including reduced risk of can-
cer, autoimmune disease, CVD, neurodegenerative dis-
orders, and T2DM [79]. The disposable soma theory of 
aging suggests that CR evolved as a somatic protection 
response to enable animals to survive periods of food 
shortage [3]. The shutdown of reproductive function 
during CR is consistent with this suggestion, but other 
TABLE 1.2 Targets and Potential Therapeutic Interventions
Targets Therapies
Elevated levels of 
IL-6, TNF-α
Monoclonal antibodies against these cytokines 
and their receptors
NSAID
Agonists of cytokine receptors or PRR 
receptors for people who do not respond to  
(or comply with) NSAID therapy
Antibody-mediated stimulation of decoy TLRs, 
such as TAM receptors, or of intracellular TLR 
regulators for people with proinflammatory 
alleles of the TLR4 and TLR2 genes
Statin therapy
Physical activity
Administration of prebiotics and probiotics: 
proinflammatory cytokine lowering, CRP 
reduction
Oxidative stress Caloric restriction: increase in the level and 
activation of adenine nucleotide translocase 
and the uncoupling proteins to reduce the 
mitochondrial membrane potential, which 
results in a decrease in superoxide radical 
(O2•−) production
Polyphenols
Mitochondria 
dysfunction
Caloric restriction: improving in SIRT1 levels
Activation of  
NF-κB pathway
Caloric restriction: improving the levels of 
sirtuin proteins
Terpenoids: resveratrol induces activation of 
sirtuins via the AMPK pathway
Use of specific miRNAs
Administration of prebiotics and probiotics
Decline of 
autophagic 
cleansing
CR: inhibition of mTOR
Rapamycin: inhibition of mTOR
Increased insulin/
IGF1 pathway
Metformin with CR mimic response
CR, caloric restriction; CRP, C-reactive protein; IL-6, interleukin-6; mTOR, 
mammalian target of rapamycin; NSAID, nonsteroidal anti-inflammatory drug; 
PRR, pattern recognition receptor; SIRT1, NAD-dependent protein deacetylase 
sirtuin-1; TAM, Tyro3/Axl/Mer; TLR, Toll-like receptor; TNF-α, tumor necrosis 
factor.
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features of the phenomenon are less consistent with this 
theory. Some researchers have, indeed, proposed that in 
rodents it may be mostly an artifact of domestication. 
CR induces profound effects on animals at all levels, 
from the transcriptome to whole animal physiology 
and behavior. Animals under CR lose weight, which is 
disproportionately contributed to by white adipose tis-
sue. Generally, animals on CR change their activity pat-
terns. Thus, they are more active prior to food delivery 
each day, but their total activity may be unchanged or 
reduced [79]. There has been considerable debate over 
the effects of CR on the resting metabolic rate (RMR). 
Total RMR declines but as body mass and body com-
position also change it is unclear whether metabolism 
at the tissue level also declines, is unchanged, or even 
increases. Body temperature universally decreases. 
Hunger is increased and does not seem to decline even 
with very long-term restriction. Circulating adipokines 
are reduced, reflecting the reduction in white adipose 
tissue mass under CR [79]. There is also a large reduction 
in circulating insulin and glucose levels. There are pro-
found tissue level changes in metabolism, with a gener-
alized shift from carbohydrate to fat metabolism. Four 
pathways have been implicated in mediating the CR 
effects: the insulin/IGF-I signaling pathway, the sirtuin 
pathway, the 5′-adenosine monophosphate (AMP)-acti-
vated protein kinase (AMPK) pathway, and the mTOR 
pathway [79]. These different pathways may interact 
and may all play important roles in mediating different 
aspects of the response. Exactly how they generate the 
health benefits remains open to debate. However, one 
of the major impacts of CR is to reduce oxidative stress 
[80]. As described above, the main cellular source of 
ROS is mitochondria. Isolated mitochondria from ani-
mals under CR show reductions in ROS production. In 
particular, CR results in increased levels and activation 
of adenine nucleotide translocase and the uncoupling 
proteins, which reduce the mitochondrial membrane 
potential, resulting in a decrease in superoxide radi-
cal (O2•−) production. This results in reduced damage 
to the lipids in the mitochondrial membrane, which is 
further reduced by increased membrane lipid saturation 
[80]. Increased levels of superoxide dismutase convert 
superoxide into hydrogen peroxide and increased lev-
els of Se-dependent glutathione peroxidase and catalase 
convert this to water, thus reducing the production of 
the toxic hydroxyl radical (HO•). Lowered levels of HO• 
reduce oxidative damage to proteins and DNA, which 
is further ameliorated by enhanced levels of protein 
degradation and base-excision repair, respectively [80]. 
Furthermore, CR induces mitochondrial biogenesis, 
as measured by changes in mtDNA levels and protein 
 levels [81]. Such effects on mitochondrial biogenesis are 
consistent with the idea that there may be a tissue level 
increase in oxygen consumption under CR, which is 
accommodated by the reduced overall energy budget of 
the reduced amount of metabolizing tissue.
In addition, CR increases the levels of members of the 
sirtuin family (SIRT1-7), NAD+-dependent deacetylases 
involved in the regulation of the activity of many pro-
teins, energy metabolism, cell survival, and longevity 
[82,83]. In particular, CR increases the expression of SIRT1 
in multiple tissues, even if this effect does not appear 
to be uniform in all tissues or across different studies 
[84]. It has been demonstrated that SIRT1 interacts with 
p65/RelA protein and specifically cleaves the acetyl 
group from lysine-310 of p65, which reduces the transacti-
vation efficiency of the NF-κB system [85,86]. Thus, SIRT1 
is a potent inhibitor of the NF-κB system. Autophagy is 
also enhanced by CR via inhibition of mTOR or activa-
tion of the AMPK pathway. This last is an evolutionary 
conserved sensor for disturbances in cellular energy bal-
ance and a major inducer of autophagy. Thus, CR acts 
directly or indirectly to inhibit the NF-κB system [79,87].
Considerable effort has been directed in recent years 
to finding drugs that mimic the CR response. Promising 
candidates are those that intersect with the critical signal-
ing pathways identified above and include biguanides 
such as metformin, capable of targeting the insulin sig-
naling pathway, stilbenes (e.g. resveratrol), which affect 
sirtuin activity, and drugs such as rapamycin that interact 
with mTOR signaling. Whether it will ever be possible to 
find drugs that capture the health benefits of CR without 
the negative side effects remains unclear [79,88,89].
As mentioned above, several plant-derived, folk medi-
cine compounds and extracts have been claimed to have 
anti-aging effects [79]. However, only a few of these tra-
ditional remedies have been subjected to clinical trials. 
Recently, many promising compounds have been iden-
tified and scrutinized. Among these are polyphenols 
(i.e. flavonoids and terpenoids), the major ingredients 
of fruits, vegetables, and different spices [79,90]. Many 
polyphenols are inhibitors of the NF-κB signaling system, 
since they are potent antioxidants; as a consequence, they 
inhibit ROS production and activation of the NF-κB sig-
naling system [91,92]. Some of them (i.e. terpenoids) can 
also directly inhibit IKK/NF-κB signaling [91]. Accord-
ingly, low-doses of terpenoids have been found to trig-
ger cellular stress response and subsequently induce 
adaptive stress resistance, a condition defined as horme-
sis [93,94]. Stress resistance involves several molecular 
adaptations via activation of the AMPK pathway and the 
subsequent increased expression of survival genes, such 
as those encoding FOXOs, p53, and sirtuins, [93,94]. Of 
special note is the effect of resveratrol, a stilbene phyto-
chemical. This induces activation of SIRT1 via the AMPK 
pathway and indirectly inhibits the NF-κB signaling sys-
tem via activation of survival genes [91].
In addition, there is promising evidence that physical 
activity has a role in reducing the levels of inflammatory 
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markers. Several theories have been advanced to explain 
this; however, the mechanisms underlying its anti-inflam-
matory effects seem complex and have not been fully elu-
cidated. It has been recently considered that the decreased 
production of proinflammatory cytokines may originate 
from a reduction in adiposity or the release of muscle-
derived IL-6 [95–98]. This last seems to induce several 
metabolic adaptations, i.e. hepatic glycogenolysis and 
lipolysis, and the release of cytokine inhibitors [i.e. IL-1ra, 
soluble TNF receptor (sTNFR), and IL-10] and cytokines 
with potent anabolic effects, such as IL-15 [95–98].
Another good target for anti-aging therapy could be 
miRNAs, which can be detected in serum and plasma 
using new advanced technologies. A good strategy could 
be the use of specific miRNAs to target genes encoding 
molecules of the NF-κB signaling system.
In addition, the administration of probiotics and/or 
prebiotics to the elderly seems to induce changes in sev-
eral inflammatory parameters (i.e. lowers proinflamma-
tory cytokines and reduces CRP), demonstrating that the 
manipulation of gut microbiota may result in modifica-
tion of the aged immune system function. On the other 
hand, intestinal microbiota seem to play a fundamen-
tal role in maintaining human health. Their supposed 
importance in human physiology has recently led human 
subjects being labeled as “metaorganisms” because of 
their close symbiotic relationship with indigenous gut 
microbiota. The “metaorganisms” hypothesis promotes 
the use of dietary supplementation with probiotics and 
prebiotics as a therapeutic strategy to preserve human 
health, particularly during the life period not foreseen by 
evolution—“aging”—that inexorably alters gut microbi-
ota composition, stability, and functionality [99].
CONCLUSIONS
Putting together the observations described above, 
chronic inflammation is emerging as a major biologi-
cal mechanism underpinning the aging process and 
age-related diseases [30–33,36]. Thus, the large array of 
defense factors and mechanisms linked to the NF-κB sys-
tem now seem to be involved in the aging process [2,24]. 
This concept leads us to propose inducers of the NF-κB 
signaling system as potential aging biomarkers and as 
promising targets for the development of new therapeu-
tic strategies against aging and age-related diseases. Some 
cellular inflammatory mechanisms and plasma molecules 
are described in this report as potential aging biomarkers. 
In addition, some suggestions on their roles as promising 
targets for the development of new therapeutic strategies 
have been discussed. Our attention has been particu-
larly focused on possible interventions in molecular sur-
vival and resistance stress pathways that may be capable 
of reducing or inhibiting the NF-κB signaling system. 
However, it is impossible to predict whether reducing 
or retarding the onset of the aging biological phenotype 
is possible by modifying lifestyle or through the use of 
CR-mimetic drugs and other preventive interventions. 
There are several reasons for being cautious. First, the 
major data on anti-aging effects have been obtained from 
studies on animals. Thus, potential therapeutic interven-
tions based on pathways identified in model organisms 
may be illusory because gains in longevity achieved in 
these organisms seem to decline with organismal com-
plexity or depend on their idiosyncratic physiology. Fur-
thermore, lifespan in some organisms may be less plastic 
than in others. In addition, there are still enormous gaps 
in our knowledge about how metabolic pathways operate 
and interact. Serious side effects may constrain the effec-
tiveness of pharmacological interventions.
The best treatment might be that which promotes 
the repair of macromolecular damage. However, it is 
unclear whether all toxic lesions associated with the 
aging process have been identified, or whether practical 
and appropriate strategies exist to eliminate them, such 
as those mentioned above.
Thus, other studies are needed to confirm and extend 
these current data. For example, genomic, transcrip-
tomic, and epigenetic investigations may eventually lead 
to a better understanding of the molecular and cellular 
inflammatory mechanisms associated with biological 
aging. In addition, for the development of human anti-
aging therapies, it would be more appropriate to identify 
cellular and serum aging biomarkers and potential tar-
gets using an appropriate model, such as the offspring 
of centenarians, i.e. healthy elderly people with a fam-
ily history of longevity, as was recently suggested [100]. 
On the other hand, research into biomarkers of aging 
and age-related diseases for understanding the health 
trajectories of the oldest old is unexplored territory. It 
is important that this knowledge gap is filled, given the 
rapid growth in the number of very old people in many 
contemporary populations. The goal of this research is 
to guarantee improving the quality of life rather than 
searching for the elixir of long life.
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